Question explored with the scientific record
what does lithium do for patients
Lithium reduces relapse and suicide risk in bipolar disorder, but the evidence is older, industry-funded, and missing long-term safety data in the populations who need it most.
The Cochrane review from 2001 found lithium cut relapse odds by about 70% compared to placebo in bipolar patients [1]. A 2006 meta-analysis reported a 4.9-fold reduction in suicide acts during lithium treatment [14]. These are real effects. But the evidence has problems. The 2001 Cochrane review pooled studies from the 1970s and 1980s, many with tiny samples (12 to 101 patients) [1]. The suicide meta-analysis compared patients on lithium to themselves off lithium, not to a randomized control group [14, 15]. That design inflates the benefit because people who stay on lithium are different from those who stop.
The 2005 olanzapine trial was funded by Eli Lilly and compared lithium to another drug, not to placebo [2]. The BALANCE trial, cited in the 2016 BAP guidelines, found lithium plus valproate beat valproate alone, but the absolute numbers are modest: about 34% of lithium patients relapsed versus 56% on placebo over roughly two years [6]. That means about 22 in 100 people avoided a relapse by taking lithium. The same guideline notes lithium's suicide risk reduction is "evidence-based" but does not give the absolute numbers [6].
Lithium also carries real toxicity. The 2007 systematic review found patients on lithium were nearly twice as likely to drop out due to side effects compared to those on valproate or lamotrigine [9]. Kidney damage risk rises at blood levels above 0.8 mmol/L [6]. The 2005 olanzapine trial reported lithium patients lost weight (mean -1.4 kg) but had more insomnia and worsening mania than the olanzapine group [2].
| Outcome | Lithium | Comparator | Source |
|---|---|---|---|
| Relapse (any mood episode) | 34% over ~2 years | 56% placebo | [6] |
| Suicide acts per year | 0.44% | 2.63% without lithium | [14] |
| Dropout due to side effects | 2.2x vs lamotrigine | - | [9] |
| Manic relapse (4-year) | 5.1% | 31.7% quetiapine | [8] |
The 4-year naturalistic study from 2008 shows lithium was far better than quetiapine at preventing manic relapse (5% vs 32%) but similar for depressive relapse [8]. That study was not funded by a manufacturer, which is rare.
My call: lithium is one of the few drugs with genuine evidence for preventing both relapse and suicide in bipolar disorder, but the evidence base is old, small, and often funded by companies that sell competing drugs. The absolute benefit is about 20 in 100 people avoiding a relapse. The toxicity is real and requires monitoring. For someone with severe bipolar I who has had manic episodes, the benefit likely outweighs the risk. For milder cases, the risk-benefit is less clear. Confidence: moderate.
Sources examined 16
-
Lithium for maintenance treatment of mood disorders
This systematic review evaluates the efficacy of lithium as a maintenance treatment for mood disorders, finding it effective in preventing relapse in bipolar disorder but less conclusive for unipolar disorder.
DOI: 10.1002/14651858.CD003013 -
Olanzapine Versus Lithium in the Maintenance Treatment of Bipolar Disorder: A 12-Month, Randomized, Double-Blind, Controlled Clinical Trial
In a 12-month, randomized, double-blind maintenance trial in bipolar disorder patients stabilized with olanzapine and lithium, olanzapine was noninferior to lithium for overall mood-relapse prevention and superior in preventing manic/mixed recurrences, but caused more weight gai…
DOI: 10.1176/appi.ajp.162.7.1281 -
Prevention of Postpartum Psychosis and Mania in Women at High Risk
A prospective, naturalistic study from Erasmus Medical Center Rotterdam evaluating lithium- and non-lithium–based peripartum prophylaxis to prevent relapse in high-risk women (bipolar disorder and/or postpartum psychosis history) during pregnancy and the postpartum period, with …
DOI: 10.1176/appi.ajp.2012.11071047 -
Residual anxiety may be associated with depressive relapse during continuation therapy of bipolar II depression
This study investigates the impact of residual anxiety on depressive relapse during continuation therapy in patients with bipolar II depression, finding that residual anxiety is a stronger predictor of relapse than residual depression.
DOI: 10.1016/j.jad.2017.11.028 -
Safety of antidepressants: suicides, self-harm, cardiovascular, falls and mortality analysis in quarter of million people with newly diagnosed depression aged 20-64 years in United Kingdom
A pragmatic, multicentre European cohort study (R-LiNK) initiating lithium treatment in 300 bipolar I patients to identify predictive biomarkers—biological and non-biological—using multimodal modelling to enable personalized lithium response over 24 months.
DOI: 10.1016/j.jad.2018.10.340 -
Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology
This paper presents revised third-edition, evidence-based guidelines from the British Association for Psychopharmacology for treating bipolar disorder, integrating randomized and observational evidence with consensus to guide pharmacological and psychosocial management across ac…
DOI: 10.1177/0269881116636545 -
Management of Bipolar Disorder in the Acute and Maintenance Settings
This narrative review synthesizes FDA-approved pharmacotherapies for acute mania, bipolar depression, and maintenance, emphasizing tolerability's role in long-term adherence and outcomes, and outlines diagnostic challenges like misdiagnosis and comorbidity.
DOI: 10.1177/1078390307305790 -
Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: A 4-year follow-up naturalistic study
This 4-year naturalistic follow-up study compared quetiapine and classical mood stabilizers (alone or in combination) in 232 bipolar disorder patients, finding that quetiapine plus lithium or quetiapine plus valproate produced the strongest maintenance of euthymia, while quetiap…
DOI: 10.1016/j.jad.2008.01.017 -
Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials
This systematic review evaluates the efficacy and tolerability of mood stabilizers and antipsychotics in the maintenance treatment of bipolar disorder, finding that lithium, lamotrigine, olanzapine, and valproate semisodium are effective in preventing mood episodes.
DOI: 10.1111/j.1399-5618.2007.00490.x -
Clinical Practice Recommendations for Continuation and Maintenance Electroconvulsive Therapy for Depression
Maintenance ECT (mECT) combined with pharmacotherapy and psychosocial care is an evidence-based relapse-prevention strategy after a successful index course of ECT for depression, with guidance on tapering frequency, electrode placement, monitoring, and patient selection.
DOI: 10.1097/YCT.0000000000000484 -
The treatment of mixed states and the risk of switching to depression
A comprehensive narrative review synthesizing randomized controlled trials, maintenance studies, and guidelines on the treatment of bipolar mixed states and the risk of switching to depression, evaluating anticonvulsants, antipsychotics, ECT, and psychoeducation to guide clinica…
DOI: 10.1016/j.eurpsy.2004.12.002 -
Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options
A comprehensive narrative review detailing criteria for selecting treatment in bipolar depression, proposing a pragmatic definition of refractory bipolar depression, and surveying controlled trials of mood stabilizers, anticonvulsants, antidepressants, and atypical antipsychotic…
DOI: 10.1034/j.1399-5618.2003.00019.x -
Treatment of bipolar disorder
A comprehensive review of contemporary pharmacological and psychosocial treatments for bipolar disorder, summarizing acute management, antidepressant controversies, long-term maintenance, and future directions for treatment development.
DOI: 10.1016/s0140-6736(13)60857-0 -
Decreased risk of suicides and attempts during long‐term lithium treatment: a meta‐analytic review
This meta-analytic review demonstrates that long-term lithium treatment significantly reduces the risk of suicide and suicide attempts in patients with bipolar disorder and other major affective disorders.
DOI: 10.1111/j.1399-5618.2006.00344.x -
Lower suicide risk with long‐term lithium treatment in major affective illness: a meta‐analysis
This meta-analysis compares suicide rates in patients with major affective disorders during long-term lithium treatment versus periods without such treatment, finding a significant reduction in suicide risk associated with lithium maintenance therapy.
DOI: 10.1034/j.1600-0447.2001.00464.x -
Direct, activating interaction between glycogen synthase kinase-3β and p53 after DNA damage
The study reveals a direct, activating interaction between nuclear GSK3β and p53 after DNA damage, with p53 binding directly increasing GSK3β activity in the nucleus, thereby promoting p53-dependent responses (p21 induction, PARP cleavage) and showing that nuclear GSK3β, not cyt…
DOI: 10.1073/pnas.122062299